Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP.
Longo D, Duffey P, DeVita V, Wiernik P, Hubbard S, Phares J, Bastian A, Jaffe E, Young R. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP. Journal Of Clinical Oncology 1991, 9: 1409-20. PMID: 1712836, DOI: 10.1200/jco.1991.9.8.1409.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBleomycinDose-Response Relationship, DrugDoxorubicinFemaleFollow-Up StudiesHodgkin DiseaseHumansLeukemiaLomustineMaleMechlorethamineMiddle AgedNeoplasm StagingPrednisoneProcarbazineRemission InductionStreptozocinSurvival RateVincristineConceptsAdvanced-stage Hodgkin's diseaseErythrocyte sedimentation rateDose intensityOverall survivalHodgkin's diseaseInitial erythrocyte sedimentation rateDisease-free survival ratesDisease-free survival curvesComplete response rateDisease-free survivalBetter overall survivalPoor prognostic factorSecondary acute leukemiaHigher platelet countsAssessable patientsPrognostic factorsPlatelet countAcute leukemiaTreatment outcomesMOPPPatientsResponse rateSurvival rateSurvival curvesDisease